{"entity":{"type":"insider","cik":"0001579179","url":"/insider/0001579179","json_url":"/insider/0001579179.json","name":"Brady Todd C","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":17,"n_filings":13,"first":"2014-05-08","last":"2026-06-05","span_basis":"filed_date"},"name_variants":[{"name":"Brady Todd C","source":"filing","n_filings":13,"first_seen":"2014-05-08","last_seen":"2026-06-05"}],"transactions":[{"id":5763226,"accession":"0001193125-26-259637","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-259637","line_url":"/filing/0001193125-26-259637#line-1","is_derivative":false,"issuer_cik":"0001341235","issuer_name":"Aldeyra Therapeutics, Inc.","issuer_ticker":"ALDX","issuer_name_source":null,"issuer_url":"/issuer/0001341235","owner_cik":"0001579179","owner_name":"Brady Todd C","owner_display_name":"Brady Todd C","owner_url":"/insider/0001579179","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":250000.0,"shares_display":"250,000","price_per_share":1.6738,"price_display":"1.67","price_state":"stated","total_value":418450.0,"total_display":"418,450.00","total_whole":"418,450","shares_owned_after":1721298.0,"shares_owned_after_display":"1,721,298","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-03","filed_date":"2026-06-05","scope":"insider"},{"id":2176102,"accession":"0000950170-24-030309","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-030309","line_url":"/filing/0000950170-24-030309#line-2","is_derivative":false,"issuer_cik":"0001341235","issuer_name":"Aldeyra Therapeutics, Inc.","issuer_ticker":"ALDX","issuer_name_source":null,"issuer_url":"/issuer/0001341235","owner_cik":"0001579179","owner_name":"Brady Todd C","owner_display_name":"Brady Todd C","owner_url":"/insider/0001579179","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":85324.0,"shares_display":"85,324","price_per_share":3.05,"price_display":"3.05","price_state":"stated","total_value":260238.2,"total_display":"260,238.20","total_whole":"260,238","shares_owned_after":1471298.0,"shares_owned_after_display":"1,471,298","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-12","filed_date":"2024-03-12","scope":"insider"},{"id":2176098,"accession":"0000950170-24-030309","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-030309","line_url":"/filing/0000950170-24-030309#line-1","is_derivative":false,"issuer_cik":"0001341235","issuer_name":"Aldeyra Therapeutics, Inc.","issuer_ticker":"ALDX","issuer_name_source":null,"issuer_url":"/issuer/0001341235","owner_cik":"0001579179","owner_name":"Brady Todd C","owner_display_name":"Brady Todd C","owner_url":"/insider/0001579179","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":97914.0,"shares_display":"97,914","price_per_share":3.2735,"price_display":"3.27","price_state":"stated","total_value":320521.479,"total_display":"320,521.48","total_whole":"320,521","shares_owned_after":1556622.0,"shares_owned_after_display":"1,556,622","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-11","filed_date":"2024-03-12","scope":"insider"},{"id":6264151,"accession":"0000899243-22-024132","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-024132","line_url":"/filing/0000899243-22-024132#line-1","is_derivative":false,"issuer_cik":"0001341235","issuer_name":"Aldeyra Therapeutics, Inc.","issuer_ticker":"ALDX","issuer_name_source":null,"issuer_url":"/issuer/0001341235","owner_cik":"0001579179","owner_name":"Brady Todd C","owner_display_name":"Brady Todd C","owner_url":"/insider/0001579179","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":17700.0,"shares_display":"17,700","price_per_share":3.3642,"price_display":"3.36","price_state":"stated","total_value":59546.34,"total_display":"59,546.34","total_whole":"59,546","shares_owned_after":1216535.0,"shares_owned_after_display":"1,216,535","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-06-23","filed_date":"2022-06-27","scope":"insider"},{"id":8545220,"accession":"0000899243-19-029509","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-029509","line_url":"/filing/0000899243-19-029509#line-1","is_derivative":false,"issuer_cik":"0001341235","issuer_name":"Aldeyra Therapeutics, Inc.","issuer_ticker":"ALDX","issuer_name_source":null,"issuer_url":"/issuer/0001341235","owner_cik":"0001579179","owner_name":"Brady Todd C","owner_display_name":"Brady Todd C","owner_url":"/insider/0001579179","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":20000.0,"shares_display":"20,000","price_per_share":5.0954,"price_display":"5.10","price_state":"stated","total_value":101908.0,"total_display":"101,908.00","total_whole":"101,908","shares_owned_after":652216.0,"shares_owned_after_display":"652,216","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-12-16","filed_date":"2019-12-18","scope":"insider"},{"id":8437995,"accession":"0000899243-19-024582","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-024582","line_url":"/filing/0000899243-19-024582#line-1","is_derivative":false,"issuer_cik":"0001341235","issuer_name":"Aldeyra Therapeutics, Inc.","issuer_ticker":"ALDX","issuer_name_source":null,"issuer_url":"/issuer/0001341235","owner_cik":"0001579179","owner_name":"Brady Todd C","owner_display_name":"Brady Todd C","owner_url":"/insider/0001579179","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":8710.0,"shares_display":"8,710","price_per_share":5.6812,"price_display":"5.68","price_state":"stated","total_value":49483.252,"total_display":"49,483.25","total_whole":"49,483","shares_owned_after":632216.0,"shares_owned_after_display":"632,216","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-09-30","filed_date":"2019-10-02","scope":"insider"},{"id":8472250,"accession":"0000899243-19-024225","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-024225","line_url":"/filing/0000899243-19-024225#line-1","is_derivative":false,"issuer_cik":"0001341235","issuer_name":"Aldeyra Therapeutics, Inc.","issuer_ticker":"ALDX","issuer_name_source":null,"issuer_url":"/issuer/0001341235","owner_cik":"0001579179","owner_name":"Brady Todd C","owner_display_name":"Brady Todd C","owner_url":"/insider/0001579179","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":8680.0,"shares_display":"8,680","price_per_share":5.8102,"price_display":"5.81","price_state":"stated","total_value":50432.536,"total_display":"50,432.54","total_whole":"50,433","shares_owned_after":623506.0,"shares_owned_after_display":"623,506","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-09-23","filed_date":"2019-09-25","scope":"insider"},{"id":8507395,"accession":"0000899243-19-023982","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-023982","line_url":"/filing/0000899243-19-023982#line-1","is_derivative":false,"issuer_cik":"0001341235","issuer_name":"Aldeyra Therapeutics, Inc.","issuer_ticker":"ALDX","issuer_name_source":null,"issuer_url":"/issuer/0001341235","owner_cik":"0001579179","owner_name":"Brady Todd C","owner_display_name":"Brady Todd C","owner_url":"/insider/0001579179","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":14288.0,"shares_display":"14,288","price_per_share":5.9116,"price_display":"5.91","price_state":"stated","total_value":84464.9408,"total_display":"84,464.94","total_whole":"84,465","shares_owned_after":614826.0,"shares_owned_after_display":"614,826","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-09-18","filed_date":"2019-09-20","scope":"insider"},{"id":9204676,"accession":"0000899243-19-023735","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-19-023735","line_url":"/filing/0000899243-19-023735#line-2","is_derivative":false,"issuer_cik":"0001341235","issuer_name":"Aldeyra Therapeutics, Inc.","issuer_ticker":"ALDX","issuer_name_source":null,"issuer_url":"/issuer/0001341235","owner_cik":"0001579179","owner_name":"Brady Todd C","owner_display_name":"Brady Todd C","owner_url":"/insider/0001579179","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3000.0,"shares_display":"3,000","price_per_share":6.03,"price_display":"6.03","price_state":"stated","total_value":18090.0,"total_display":"18,090.00","total_whole":"18,090","shares_owned_after":600538.0,"shares_owned_after_display":"600,538","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-09-16","filed_date":"2019-09-17","scope":"insider"},{"id":8608829,"accession":"0000899243-19-023718","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-19-023718","line_url":"/filing/0000899243-19-023718#line-2","is_derivative":false,"issuer_cik":"0001341235","issuer_name":"Aldeyra Therapeutics, Inc.","issuer_ticker":"ALDX","issuer_name_source":null,"issuer_url":"/issuer/0001341235","owner_cik":"0001579179","owner_name":"Brady Todd C","owner_display_name":"Brady Todd C","owner_url":"/insider/0001579179","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3000.0,"shares_display":"3,000","price_per_share":6.03,"price_display":"6.03","price_state":"stated","total_value":18090.0,"total_display":"18,090.00","total_whole":"18,090","shares_owned_after":591991.0,"shares_owned_after_display":"591,991","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-09-16","filed_date":"2019-09-17","scope":"insider"},{"id":9204675,"accession":"0000899243-19-023735","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-023735","line_url":"/filing/0000899243-19-023735#line-1","is_derivative":false,"issuer_cik":"0001341235","issuer_name":"Aldeyra Therapeutics, Inc.","issuer_ticker":"ALDX","issuer_name_source":null,"issuer_url":"/issuer/0001341235","owner_cik":"0001579179","owner_name":"Brady Todd C","owner_display_name":"Brady Todd C","owner_url":"/insider/0001579179","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":18547.0,"shares_display":"18,547","price_per_share":5.8963,"price_display":"5.90","price_state":"stated","total_value":109358.6761,"total_display":"109,358.68","total_whole":"109,359","shares_owned_after":597538.0,"shares_owned_after_display":"597,538","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-09-13","filed_date":"2019-09-17","scope":"insider"},{"id":8608824,"accession":"0000899243-19-023718","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-023718","line_url":"/filing/0000899243-19-023718#line-1","is_derivative":false,"issuer_cik":"0001341235","issuer_name":"Aldeyra Therapeutics, Inc.","issuer_ticker":"ALDX","issuer_name_source":null,"issuer_url":"/issuer/0001341235","owner_cik":"0001579179","owner_name":"Brady Todd C","owner_display_name":"Brady Todd C","owner_url":"/insider/0001579179","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":5.79,"price_display":"5.79","price_state":"stated","total_value":57900.0,"total_display":"57,900.00","total_whole":"57,900","shares_owned_after":588991.0,"shares_owned_after_display":"588,991","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-09-13","filed_date":"2019-09-17","scope":"insider"},{"id":8413819,"accession":"0000899243-19-023317","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-19-023317","line_url":"/filing/0000899243-19-023317#line-2","is_derivative":false,"issuer_cik":"0001341235","issuer_name":"Aldeyra Therapeutics, Inc.","issuer_ticker":"ALDX","issuer_name_source":null,"issuer_url":"/issuer/0001341235","owner_cik":"0001579179","owner_name":"Brady Todd C","owner_display_name":"Brady Todd C","owner_url":"/insider/0001579179","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":5.3937,"price_display":"5.39","price_state":"stated","total_value":53937.0,"total_display":"53,937.00","total_whole":"53,937","shares_owned_after":578991.0,"shares_owned_after_display":"578,991","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-09-10","filed_date":"2019-09-11","scope":"insider"},{"id":8413817,"accession":"0000899243-19-023317","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-023317","line_url":"/filing/0000899243-19-023317#line-1","is_derivative":false,"issuer_cik":"0001341235","issuer_name":"Aldeyra Therapeutics, Inc.","issuer_ticker":"ALDX","issuer_name_source":null,"issuer_url":"/issuer/0001341235","owner_cik":"0001579179","owner_name":"Brady Todd C","owner_display_name":"Brady Todd C","owner_url":"/insider/0001579179","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":4.8887,"price_display":"4.89","price_state":"stated","total_value":48887.0,"total_display":"48,887.00","total_whole":"48,887","shares_owned_after":568991.0,"shares_owned_after_display":"568,991","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-09-09","filed_date":"2019-09-11","scope":"insider"},{"id":4886082,"accession":"0000899243-17-004754","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-17-004754","line_url":"/filing/0000899243-17-004754#line-1","is_derivative":false,"issuer_cik":"0001341235","issuer_name":"Aldeyra Therapeutics, Inc.","issuer_ticker":"ALDX","issuer_name_source":null,"issuer_url":"/issuer/0001341235","owner_cik":"0001579179","owner_name":"Brady Todd C","owner_display_name":"Brady Todd C","owner_url":"/insider/0001579179","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":22223.0,"shares_display":"22,223","price_per_share":4.5,"price_display":"4.50","price_state":"stated","total_value":100003.5,"total_display":"100,003.50","total_whole":"100,004","shares_owned_after":64408.0,"shares_owned_after_display":"64,408","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-02-17","filed_date":"2017-02-21","scope":"insider"},{"id":6593280,"accession":"0001209191-14-059572","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-14-059572","line_url":"/filing/0001209191-14-059572#line-1","is_derivative":false,"issuer_cik":"0001403708","issuer_name":"Evoke Pharma Inc","issuer_ticker":"EVOK","issuer_name_source":null,"issuer_url":"/issuer/0001403708","owner_cik":"0001579179","owner_name":"Brady Todd C","owner_display_name":"Brady Todd C","owner_url":"/insider/0001579179","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4000.0,"shares_display":"4,000","price_per_share":5.7004,"price_display":"5.70","price_state":"stated","total_value":22801.6,"total_display":"22,801.60","total_whole":"22,802","shares_owned_after":4000.0,"shares_owned_after_display":"4,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-09-23","filed_date":"2014-09-24","scope":"insider"},{"id":6763264,"accession":"0001209191-14-032368","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-14-032368","line_url":"/filing/0001209191-14-032368#line-1","is_derivative":false,"issuer_cik":"0001341235","issuer_name":"Aldeyra Therapeutics, Inc.","issuer_ticker":"ALDX","issuer_name_source":null,"issuer_url":"/issuer/0001341235","owner_cik":"0001579179","owner_name":"Brady Todd C","owner_display_name":"Brady Todd C","owner_url":"/insider/0001579179","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":12500.0,"shares_display":"12,500","price_per_share":8.0,"price_display":"8.00","price_state":"stated","total_value":100000.0,"total_display":"100,000.00","total_whole":"100,000","shares_owned_after":15089.0,"shares_owned_after_display":"15,089","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-05-07","filed_date":"2014-05-08","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":17,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":15,"open_market":true},{"code":"S","label":"Open-market sale","n":2,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":17},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001341235","name":"Aldeyra Therapeutics, Inc.","url":"/issuer/0001341235","role":"Director, Officer (President and CEO)","n_filings":12,"first_seen":"2014-05-08","last_seen":"2026-06-05"},{"type":"issuer","type_label":"ISSUER","cik":"0001403708","name":"Evoke Pharma Inc","url":"/issuer/0001403708","role":"Director","n_filings":1,"first_seen":"2014-09-24","last_seen":"2014-09-24"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001579179","retrieved_at":"2026-08-22T23:53:29+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}